RARE DISEASE THERAPEUTICS, INC.
RARE DISEASE THERAPEUTICS, INC. has won 29 federal awards worth $369K in total across 3 agencies, with a median award of $46K. See where they win and what those contracts close for, and forecast the price on a solicitation you're competing for.
Recent awards
| Title | Agency | Value | Date |
|---|---|---|---|
| ANAVORX DISTRIBUTION LLC, ANASCORP ANTIVENOM, WRSU PHARMACY DEPT, DO/T | Department Of Health And Human Services | $46K | 2026-06-15 |
| ANOVORX DISTRIBUTION, ANASCORP INJECTION, WRSU PHARMACY DEPT | Department Of Health And Human Services | $46K | 2025-08-26 |
| ANAVORX DISTRIBUTION, ANASCORP SCORPTOIN ANTIVENOM, CRSU PHARMACY DEPT | Department Of Health And Human Services | $13K | 2025-07-30 |
| ANOVORX DISRTIBUTION, ANASCORP SCORPION ANTIVENOM, HAVASUPAI HEALTH CE | Department Of Health And Human Services | $13K | 2025-07-29 |
| ANNOVORX DISTRIBUTION LLC, ANASCROP SCORPION ANTIVENOM, PIMC PHARMACY | Department Of Health And Human Services | $49K | 2025-07-25 |
Questions
How many federal contracts has RARE DISEASE THERAPEUTICS, INC. won?
29 awards on record, worth $369K in total across 3 agencies. The median award is $46K.
Which agencies buy from RARE DISEASE THERAPEUTICS, INC.?
Mostly Department Of Health And Human Services, Department Of Veterans Affairs.
Is RARE DISEASE THERAPEUTICS, INC. a competitor worth watching?
That depends on your category. This page lists the agencies they win from and their recent awards, so you can see whether they are active in the lanes you bid. AwardCast forecasts the closing price for a specific open solicitation, which is the number that matters when you are bidding against them.
Agencies they win from
Forecast Report — what a specific solicitation will close for: the predicted price range, the competition to expect, and comparable awards already closed. Before you price your bid.
Every forecast is scored against the real award once it becomes public. See the track record.
$49 per report. No subscription, no account needed to see pricing.
